149 related articles for article (PubMed ID: 33819121)
1. Real-world assessment of "OFF" episode-related healthcare resource utilization among patients with Parkinson's disease in the United States.
Thach A; Jones E; Pappert E; Pike J; Wright J; Gillespie A
J Med Econ; 2021; 24(1):540-549. PubMed ID: 33819121
[TBL] [Abstract][Full Text] [Related]
2. Real-world assessment of the impact of "OFF" episodes on health-related quality of life among patients with Parkinson's disease in the United States.
Thach A; Jones E; Pappert E; Pike J; Wright J; Gillespie A
BMC Neurol; 2021 Jan; 21(1):46. PubMed ID: 33516182
[TBL] [Abstract][Full Text] [Related]
3. Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries.
Malaty IA; Martinez-Martin P; Chaudhuri KR; Odin P; Skorvanek M; Jimenez-Shahed J; Soileau MJ; Lindvall S; Domingos J; Jones S; Alobaidi A; Jalundhwala YJ; Kandukuri PL; Onuk K; Bergmann L; Femia S; Lee MY; Wright J; Antonini A
BMC Neurol; 2022 Jan; 22(1):35. PubMed ID: 35073872
[TBL] [Abstract][Full Text] [Related]
4. Healthcare resource utilization and device-aided therapy discussions with eligible patients across the Parkinson's disease continuum: Revelations from the MANAGE-PD validation cohort.
Fernandez HH; Odin P; Standaert DG; Henriksen T; Jimenez-Shahed J; Metz S; Alobaidi A; Yan CH; Kukreja P; Parra JC; Zamudio J; Onuk K; Wright J; Antonini A
Parkinsonism Relat Disord; 2023 Nov; 116():105514. PubMed ID: 37563079
[TBL] [Abstract][Full Text] [Related]
5. A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom.
Denee T; Ming T; Waller J; Bailey T; Rajkovic-Hooley O; Middleton-Dalby C; Le HH; Zhang Q; McCrone P; Taylor D
Curr Med Res Opin; 2021 Feb; 37(2):311-319. PubMed ID: 33253055
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
[TBL] [Abstract][Full Text] [Related]
7. Incremental health care resource utilization and costs associated among patients with Parkinson's disease psychosis and incident dementia: An analysis of medicare beneficiaries.
Rajagopalan K; Rashid N; Gopal D; Doshi D
Int J Geriatr Psychiatry; 2023 Nov; 38(11):e6017. PubMed ID: 37936540
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
Groenendaal H; Tarrants ML; Armand C
Clin Drug Investig; 2010; 30(11):789-98. PubMed ID: 20818839
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of specialized nursing interventions for people with Parkinson's disease: the NICE-PD study protocol for a randomized controlled clinical trial.
Radder DLM; Lennaerts HH; Vermeulen H; van Asseldonk T; Delnooz CCS; Hagen RH; Munneke M; Bloem BR; de Vries NM
Trials; 2020 Jan; 21(1):88. PubMed ID: 31941538
[TBL] [Abstract][Full Text] [Related]
10. Healthcare costs and resource utilization in patients with severe aplastic anemia in the US.
Cai B; Said Q; Li X; Li FY; Arcona S
J Med Econ; 2019 Oct; 22(10):1055-1062. PubMed ID: 31296074
[No Abstract] [Full Text] [Related]
11. Real-World Experiences of Parkinson's Disease OFF Time and Role of Demographics.
Devraj R; Elkouzi A; Tracey MR
J Patient Cent Res Rev; 2024; 11(1):8-17. PubMed ID: 38596350
[TBL] [Abstract][Full Text] [Related]
12. Agitation in Dementia: Real-World Impact and Burden on Patients and the Healthcare System.
Jones E; Aigbogun MS; Pike J; Berry M; Houle CR; Husbands J
J Alzheimers Dis; 2021; 83(1):89-101. PubMed ID: 34250934
[TBL] [Abstract][Full Text] [Related]
13. Compliance with pharmacotherapy and direct healthcare costs in patients with Parkinson's disease: a retrospective claims database analysis.
Richy FF; Pietri G; Moran KA; Senior E; Makaroff LE
Appl Health Econ Health Policy; 2013 Aug; 11(4):395-406. PubMed ID: 23649891
[TBL] [Abstract][Full Text] [Related]
14. Multi-National, Cross-Sectional Survey of Healthcare Resource Utilization in Patients with All Stages of Cognitive Impairment, Analyzed by Disease Severity, Country, and Geographical Region.
Khandker RK; Ritchie CW; Black CM; Wood R; Jones E; Hu X; Ambegaonkar BM
J Alzheimers Dis; 2020; 75(4):1141-1152. PubMed ID: 32390613
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa.
Hansen RN; Suh K; Serbin M; Yonan C; Sullivan SD
J Med Econ; 2021; 24(1):563-569. PubMed ID: 33866942
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the direct medical cost, drug utilization and expenditure for managing Parkinson's disease: a costing study at a medical center in China.
Yi ZM; Li XY; Wang YB; Wang RL; Ma QC; Zhao RS; Chen LC
Ann Transl Med; 2022 Mar; 10(6):330. PubMed ID: 35433954
[TBL] [Abstract][Full Text] [Related]
17. Economic burden of congenital athymia in the United States for patients receiving supportive care during the first 3 years of life.
Collins C; Kim-Chang JJ; Hsieh E; Silber A; O'Hara M; Kulke S; Cooper MA
J Med Econ; 2021; 24(1):962-971. PubMed ID: 34324414
[TBL] [Abstract][Full Text] [Related]
18. Real-world evidence from a European cohort study of patients with treatment resistant depression: Healthcare resource utilization.
Heerlein K; De Giorgi S; Degraeve G; Frodl T; Hagedoorn W; Oliveira-Maia AJ; Otte C; Perez Sola V; Rathod S; Rosso G; Sierra P; Vita A; Morrens J; Rive B; Mulhern Haughey S; Kambarov Y; Young AH
J Affect Disord; 2022 Feb; 298(Pt A):442-450. PubMed ID: 34742998
[TBL] [Abstract][Full Text] [Related]
19. Short- and long-term cost and utilization of health care resources in Parkinson's disease in the UK.
Weir S; Samnaliev M; Kuo TC; Tierney TS; Walleser Autiero S; Taylor RS; Schrag A
Mov Disord; 2018 Jul; 33(6):974-981. PubMed ID: 29603405
[TBL] [Abstract][Full Text] [Related]
20. Real-World Healthcare Resource Utilization and Cost Burden Assessment for Adults With Generalized Myasthenia Gravis in the United States.
Phillips G; Abreu C; Goyal A; Li Y; Whangbo A; Gelinas D; Brauer E; Bhattacharya S
Front Neurol; 2021; 12():809999. PubMed ID: 35115997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
